Decreased expression and activity of XPNPEP2 have been reported in hypertensive patients (Cilia La Corte et al., 2011), whereas overexpression of XPNPEP2 has been reported in patients with cervical cancer and clear-cell renal cell carcinoma (Cheng et al., 2017; Wang et al., 2020). Here, XPNPEP2 is linked to cervical cancer.